Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
Schwab C, English D, Black J, Lopez S, Bellone S, Roque D, Ratner E, Silasi D, Azodi M, Rutherford T, Schwartz P, Santin A. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo. Gynecologic Oncology 2015, 137: 61. DOI: 10.1016/j.ygyno.2015.01.142.Peer-Reviewed Original ResearchErbB receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsTreatment of HER2Tyrosine kinase inhibitorsKinase inhibitors